BridgeBio Pharma, Inc.

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: US10806X1028

USD

74.76

3.3 (4.62%)

Dec 04

NAS

Click here to see other stocks

Company CV

About BridgeBio Pharma, Inc.

stock-summary

BridgeBio Pharma, Inc.

Pharmaceuticals & Biotechnology

BridgeBio Pharma, Inc. is discovering and developing medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-265, BBP-831, BBP-631 and BBP-454.

Company Coordinates

Company Details

421 Kipling St , PALO ALTO CA : 94301-1530

stock-summary

Tel: 1 650 3919740

stock-summary

http://bridgebio.com/

stock-summary

Registrar Details

Shareholding

Shareholding Snapshot

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Domestic Funds

Held in 83 Schemes (28.04%)

Foreign Institutions

Held by 140 Foreign Institutions (13.03%)

Strategic Entities with highest holding

Highest Public shareholder

Board of Directors

Management

Designation

Dr. Neil Kumar

Chief Executive Officer, Director

Dr. Charles Homcy

Chairman of Pharmaceuticals, Lead Director

Dr. Richard Scheller

Chairman of Research and Development, Director

Dr. Eric Aguiar

Independent Director

Ms. Jennifer Cook

Independent Director

Mr. Ronald Daniels

Independent Director

Andrew Lo

Independent Director

Mr. James Momtazee

Independent Director

Stock DNA

Revenue and Profits:

Net Sales:

111 Million

(Quarterly Results - Jun 2025)

Net Profit:

-184 Million

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 10,715 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

NA

Dividend Yield

0.00%

Debt Equity

-1.07

Return on Equity

42.43%

Price to Book

-5.99